Shenzhen Weiguang Biological Products Co., Ltd. (hereinafter referred to as the Company) and all members of the Board of Directors guarantee that the content of this information disclosure is true, accurate, and complete, without false records, misleading statements, or significant omissions.
The Company recently received the Drug Clinical Trial Approval Notice for human coagulation factor IX (Notice No.: 2026LP01671) issued by the National Medical Products Administration. The relevant information is announced as follows: